268 top medical experts on Smoldering Multiple Myeloma across 32 countries and 25 U.S. states, including 153 MDs (Physicians). This is based on an objective analysis of their Scientific Publications, Clinical Trials, Medicare, and NIH Grants.

  1. Smoldering Multiple Myeloma: An asymptomatic and slow-growing plasma cell dyscrasia characterized by presence of myeloma proteins and clonal bone marrow plasma cells without end-organ damage (e.g., renal impairment). It is distinguished from monoclonal gammopathy OF undetermined significance by a much higher risk of progression to symptomatic multiple myeloma.
  2. Clinical guidelines are the recommended starting point to understand initial steps and current protocols in any disease or procedure:
  3. Broader Categories (#Experts): Hypergammaglobulinemia (970), Paraproteinemias (1,357), Precancerous Conditions (4,277).
  4. Clinical Trials ClinicalTrials.gov : at least 79 including 14 Active, 15 Completed, 27 Recruiting


  

        

                    


    Computing Expert Listing ...

);